TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.
J Natl Cancer Inst
; 106(7)2014 Jul.
Article
in En
| MEDLINE
| ID: mdl-24957073
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Rectal Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Tumor Suppressor Protein p53
/
Neoadjuvant Therapy
/
Antibodies, Monoclonal, Humanized
/
Mutation
Type of study:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Natl Cancer Inst
Year:
2014
Document type:
Article
Country of publication:
United States